AGIO vs TECH · rev $36.5M vs P/E 65, rev $1.22B
Agios Pharm (AGIO) versus Bio-Techne Corp (TECH) — a side-by-side from cached financials, not a winner call.
Agios Pharm (AGIO) is a biotechnology company listed on US.
Bio-Techne Corp (TECH) is a biotechnology company listed on US.
Latest reported AGIO revenue for 2024-12-31 was $36.5M. Net income was $673.7M. Revenue was up 36.1% from 2023-12-31 to 2024-12-31. AGIO currently screens at market cap $1.68B.
Latest reported TECH revenue for 2025-06-30 was $1.22B. Net income was $73.4M. Revenue was up 5.2% from 2024-06-30 to 2025-06-30. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
AGIO currently screens at market cap $1.68B. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
Not investment advice. Open the AGIO and TECH stock pages for the full models.
Not investment advice.